STATUS DECISION OF CONTROLLED AND NON-CONTROLLED SUBSTANCE(S)

Substance: A-796,260

Based on the current information available to the Office of Controlled Substances, it appears that the above substance is:

- Controlled ✔
- Not Controlled □

under the schedules of the Controlled Drugs and Substances Act (CDSA) for the following reason(s):

- The substance is an efficacious cannabinoid CB2 receptor agonist and therefore is included under item 1 of Schedule II to the CDSA.

Prepared by: ________________________________ Date: ________________

Vincent Marleau

Verified by: ________________________________ Date: ________________

Mark Kozlowski

Approved by: ________________________________ Date: ________________

DIRECTOR, OFFICE OF CONTROLLED SUBSTANCES

This status was requested by: “third party information removed as per agreement with applicant”
Drug Status Report

Drug: A-796,260

Drug Name Status: A-796,260 is the common name.

Chemical Name: A-796,260

Other Names:
1-(2-morpholin-4-ylethyl)-1H-indol-3-yl]-(2,2,3,3-tetramethylcyclopropyl)methanone

Chemical structure:

Molecular Formula: C_{22}H_{30}N_{2}O_{2}  
CAS-RN: 895155-26-7

Pharmacological class / Application: CB2 receptor agonist

International status:
US: A-796,260 is not listed specifically in the Schedules to the US Controlled Substances Act and is not mentioned anywhere on the DEA website.

United Nations: The substance is not listed on the Yellow List - List of Narcotic Drugs under International Control, the Green List - List of Psychotropic Substances under International Control, nor the Red List - List of Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances under International Control.

Canadian Status: A-796,260 is not listed in the Schedules to the CDSA. The substance is a synthetic cannabinoid and has been reported in the scientific literature to display a strong binding affinity for the cannabinoid CB2 receptor (Ki= 4.37 ± 13.0 nM)\textsuperscript{1}. In addition, the substance has also been reported to be an efficacious CB2 cannabinoid receptor agonist in \textit{in vivo} studies\textsuperscript{1} and therefore is captured under the heading “Cannabis, its preparations, derivatives and similar synthetic preparations, including” of item 1 of Schedule II to the CDSA.

Recommendation: A-796,260 is included under item 1 of Schedule II to the CDSA and is a controlled substance.

Date: November 2\textsuperscript{nd}, 2012.